CTIC
$3.05
Cti Biopharm
CTIC
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.22)
Revenue:  $0.00 Mil
Thursday
Nov 4
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CTIC reports earnings?
Beat
Meet
Miss

Where is CTIC's stock price going from here?
Up
Flat
Down
Stock chart of CTIC
Analysts
Summary of analysts' recommendations for CTIC
Score
Grade
Pivots
Resistance
$3.13
$3.11
$3.08

$3.06

Support
$3.03
$3.01
$2.98
Tweet
Growth
Description
CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington.
Peers
Vertex PharmaceuticalsRegeneron PharmaceuticalsUltragenyx PharmaceuticalBioMarin PharmaceuticalBristol-Myers SquibbInterCeptPfizerMerck & Co.ZoetisEli Lilly